OS Therapies Inc 10-Q

Item 1. Financial Statements OS Therapies Incorporated Consolidated Balance Sheets (unaudited) September 30, 2025 December 31, 2024 Current Assets Cash $ 1,876,626 $ 5,533,527 Employee Advances 41,852 - Prepaid Expenses 403,213 - Total Current Assets 2,321,691 5,533,527 Long-Term Assets Fixed Assets (Net) 3,185 5,270 Patents (Net of Amortization) 6,628,375 - TOTAL ASSETS $ 8,953,251 $ 5,538,797 LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT Current Liabilities Accounts Payable $ 3,374,287 $ 1,662,068 Accrued Expenses 395,450 521,010 Accrued Payroll and Payroll Taxes – Related Party - 97,257 Accrued Payroll and Payroll Taxes 614 - Preferred Dividends Payable 375,000 375,000 Warrant Liability - 1,971,975 Total Current Liabilities 4,145,351 4,627,310 Long-Term Liabilities TEDCO Grant 100,000 100,000 Total Long-Term Liabilities 100,000 100,000 Total Liabilities 4,245,351 4,727,310 Commitments and contingencies (See Note 6) MEZZANINE EQUITY: Series A Convertible Preferred Stock, par value $ 0.001 , 2,500,000 shares authorized; 392,500 and 1,512,500 issued and outstanding, respectively 1,070,705 4,078,025 Total Mezzanine Equity 1,070,705 4,078,025 STOCKHOLDERS’ EQUITY (DEFICIT) Common Stock A, par value $ 0.001 , 50,000,000 shares authorized; 33,269,981 and 20,869,908 issued and outstanding, respectively 33,270 20,870 Preferred Stock, par value $ 0.001 , 5,000,000 shares authorized; 0 and 0 issued and outstanding, respectively - - Additional paid-in capital 57,329,311 35,144,967 Accumulated deficit ( 53,725,386 ) ( 38,432,375 ) Total Stockholders’ Equity (Deficit) 3,637,195 ( 3,266,538 ) TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY (DEFICIT) $ 8,953,251 $ 5,538,797 The accompanying notes are an integral part of these unaudited consolidated financial statements. 1 OS Therapies Incorporated Consolidated Statements of Operations (unaudited) For the three months ended For the three months ended For the nine months ended For the nine months ended September 30, September 30, September 30, September 30, 2025 2024 2025 2024 OPERATING EXPENSES Research & Development $ 3,755,335 $ 1,210,216 $ 7,563,988 $ 1,968,591 General & Administrative 3,124,260 1,227,177 9,153,821 1,878,831 Loss from Operations ( 6,879,595 ) ( 2,437,393 ) ( 16,717,809 ) ( 3,847,422 ) OTHER INCOME/EXPENSE Interest Income 65 — 195 1 Interest Expense — ( 437,839 ) — ( 2,044,283 ) Change in Fair Value of Warrant Liability — — 1,424,603 — TOTAL OTHER INCOME/EXPENSE 65 ( 437,839 ) 1,424,798 ( 2,044,282 ) NET LOSS ( 6,879,530 ) ( 2,875,232 ) ( 15,293,011 ) ( 5,891,704 ) Cumulative Series A Preferred Stock Dividend Requirement — — — ( 31,250 ) NET LOSS available to common shareholders $ ( 6,879,530 ) $ ( 2,875,232 ) $ ( 15,293,011 ) $ ( 5,922,954 ) Weighted Average # of Shares 31,956,686 15,897,460 27,390,472 9,249,951 Basic & Diluted Loss per Common Share Outstanding $ ( 0.21 ) $ ( 0.18 ) $ ( 0.57 ) $ ( 0.64 ) The accompanying notes are an integral part of these unaudited consolidated financial statements . 2 OS Therapies Incorporated Consolidated Statements of Stockholders’ Equity (Deficit) For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) Common Stock Preferred Stock Additional Total CS – Shares Shares Par Paid-in Accumulated Stockholders’ CS – Par Amount Capital Deficit Equity (Deficit) Balances, December 31, 2023 5,340,000 $ 5,340 1,302,082 1,302 $ 5,495,330 $ ( 29,518,187 ) $ ( 24,016,215 ) Conversion of Preferred Stock to Common Stock 651,041 651 ( 1,302,082 ) ( 1,302 ) 651 - - Preferred Dividends - - - - - ( 31,250 ) ( 31,250 ) Net Loss - - - - - ( 1,458,992 ) ( 1,458,992 ) Balances, March 31, 2024 5,991,041 $ 5,991 - $ - $ 5,495,981 $ ( 31,008,429 ) $ ( 25,506,457 ) Net Loss - - - - - ( 1,557,480 ) ( 1,557,480 ) Balances, June 30, 2024 5,991,041 $ 5,991 - $ - $ 5,495,981 $ ( 32,565,909 ) $ ( 27,063,937 ) Issuance of Common Stock IPO 1,600,000 1,600 - - 4,473,626 - 4,475,226 Conversion of Convertible Notes to Common Stock 13,153,396 13,153 - - 24,743,662 - 24,756,815 Conversion of Warrants to Common Stock 116,313 116 - - ( 116 ) - - Issuance of Common Stock to Investment Advisor - Settlement 320,133 320 - - ( 320 ) - - Net Loss - - - - - ( 2,875,232 ) ( 2,875,232 ) Balances, September 30, 2024 21,180,883 $ 21,180 - $ - $ 34,712,833 $ ( 35,441,141 ) $ ( 707,128 ) Balances, December 31, 2024 20,869,908 $ 20,870 - $ - $ 35,144,967 $ ( 38,432,375 ) $ ( 3,266,538 ) Commitment shares issued for Equity Line of Credit 157,407 157 - - 568,078 - 568,235 Shares issued for Services 320,000 321 - - 1,446,980 - 1,447,301 Stock-based compensation - - - - 941,283 - 941,283 Net Loss - - - - - ( 3,876,859 ) ( 3,876,859 ) Balances, March 31, 2025 21,347,315 $ 21,348 - $ - $ 38,101,308 $ ( 42,309,234 ) $ ( 4,186,578 ) Conversion of Preferred Shares Mezzanine Equity to Common Stock 3,962,129 3,962 - - 2,988,070 - 2,992,032 Issuance Common Stock Patent License 2,164,215 2,164 - - 3,492,900 - 3,495,064 Conversion of Warrants to Common Stock 2,181,257 2,181 - - 2,481,284 - 2,483,465 Common Stock Shares issued for Services 10,000 10 - - 9,990 - 10,000 APIC Warrants Liability Reclass Preferred Stock - - - - 878,153 - 878,153 APIC Warrants Patent License - - - - 2,902,951 - 2,902,951 Stock-based compensation - - - - 905,182 - 905,182 Net Loss - - - - - ( 4,536,622 ) ( 4,536,622 ) Balances, June 30, 2025 29,664,916 $ 29,665 - $ - $ 51,759,838 $ ( 46,845,856 ) $ 4,943,647 Conversion of Preferred Shares Mezzanine Equity to Common Stock 977,679 978 - - 737,111 - 738,089 Common Stock Shares issued for Services 120,000 120 - - 239,133 - 239,253 Conversion of Warrants to Common Stock 2,507,386 2,507 - - 2,728,298 - 2,730,805 APIC Warrants Purchase of Prepaid Warrants - - - - 1,050,000 - 1,050,000 Stock-based compensation - - - - 814,931 - 814,931 Net Loss - - - - - ( 6,879,530 ) ( 6,879,530 ) Balances, September 30, 2025 33,269,981 $ 33,270 - $ - $ 57,329,311 $ ( 53,725,386 ) $ 3,637,195 The accompanying notes are an integral part of these unaudited consolidated financial statements . 3 OS Therapies Incorporated Consolidated Statements of Cash Flows For the Nine Months Ended September 30, 2025 and 2024 (unaudited) Nine Months Ended September 30, 2025 Nine Months Ended September 30, 2024 CASH FLOWS FROM OPERATING ACTIVITIES Net loss $ ( 15,293,011 ) $ ( 5,891,704 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and Amortization expense 238,147 1,390 Amortization of Debt Discounts Issuance and Warrants - 1,425,679 Change in value of Warrant Liabilities ( 1,424,603 ) - Commitment Shares issued for Equity Line of Credit 568,235 - Common Shares issuance for services 595,841 - Stock-based Compensation 2,661,397 - Adjustments to reconcile net loss to net cash used in operating activities: Prepaid Expenses 697,500 ( 35,000 ) Employee Advances ( 41,852 ) ( 77,500 ) Accounts Payable 1,712,219 ( 943,434 ) Accrued Expenses ( 125,560 ) 133,900 Accrued Interest on Convertible Notes - 613,605 Accrued Payroll and payroll taxes ( 96,643 ) ( 134,654 ) Net cash used in operating activities ( 10,508,330 ) ( 4,907,718 ) CASH FLOWS FROM INVESTING ACTIVITIES Patent License Acquisition ( 466,423 ) - Net cash used in investing activities ( 466,423 ) - CASH FLOWS FROM FINANCING ACTIVITIES Sale of Preferred Stock and related Warrants 1,053,582 - Common Stock Issuance for Warrant Exercise 6,264,270 - Short-Term Borrowings - 250,000 Short-Term Loan Repayments - ( 250,000 ) Initial Public Offering (Net of Fees) - 5,225,840 Net Proceeds from Conversion of Debt A, B, C, D, E & F - 1,501,000 Net cash provided by financing activities 7,317,852 6,726,840 Net change in cash ( 3,656,901 ) 1,819,122 Cash – beginning of period 5,533,527 38,982 Cash – end of period $ 1,876,626 $ 1,858,104 Cash paid for interest $ - $ - NON CASH INVESTING AND FINANCING ACTIVITIES Discount on Notes Payable – redemption premium - 750,500 Dividends Payable - 31,250 Mezzanine Equity Conversion (Net of Costs) 3,730,121 - Conversion of Preferred Stock to Common Stock - 1,302 Amortization of deferred offering costs - 751,050 Conversion of Convertible Notes into Common Stock - 24,757,252 Conversion of Warrants into Common Stock - 116 Issuance of Common Stock to Investor Advisor - Settlement - 320 Common Stock issued for Patent Purchase 6,398,015 - Reclassification of Warrants Liability to equity 878,153 - Shares issued for prepaid services $ 1,100,713 $ - The accompanying notes are an integral part of these unaudited consolidated financial statements. 4 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 1 — ORGANIZATION AND DESCRIPTION OF BUSINESS, LIQUIDITY, AND RISK FACTORS OS Therapies Incorporated (“we,” “us,” “our,” the “Company”) is a Delaware corporation incorporated on June 24, 2019 . It is based in Rockville, Maryland. The Company is the successor to an LLC formed in 2018. The Company intends to focus on the identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. As of September 30, 2025, there is one ongoing clinical trial for Osteosarcoma therapy. OS Animal Health Corp – Subsidiary The Company formed OS Animal Health Corp, a Delaware corporation and wholly owned subsidiary of the Company, on June 25, 2025. The entity is a shell at present and has no assets or liabilities. During the three months ended June 30, 2025, the Company entered into a license agreement with this subsidiary, pursuant to which the Company licensed to this subsidiary the rights to use the HER2 Assets (as defined below). OS Therapies UK LTD – Subsidiary The Company formed OS Therapies UK LTD, a corporation formed in the United Kingdom and wholly owned subsidiary of the Company, on August 29, 2025. The entity is a shell at present and has no assets or liabilities. The Company intends on entering into a loan agreement that is pending with this subsidiary, pursuant to which the Company will move all research and development activities to this entity. Liquidity The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company’s ability to continue as a going concern. As of September 30, 2025, the Company had cash of $ 1,876,626 . For the foreseeable future, the Company’s ability to continue its operations is dependent upon its ability to obtain additional capital. The Company is currently seeking to raise additional capital through a public or private financing of equity; although there can be no assurances the Company will be successful in such a campaign. 5 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of U.S. Securities and Exchange Commission (“SEC”). The accounting and reporting policies of the Company conform to accounting principles generally accepted in the United States of America, and the Company’s fiscal year end is December 31. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned and majority-owned subsidiaries. The Company consolidates all entities in which it has a controlling financial interest. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in its consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates. Cash Cash consists primarily of deposits with commercial banks and financial institutions. The Company maintains cash balances at various financial institutions. Both interest and non-interest-bearing accounts with the same insured depository institution are insured by the Federal Deposit Insurance Corporation (FDIC) for a combined total of $ 250,000 . In the normal course of business, the Company may have deposits that exceed the FDIC insured limit. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. As of September 30, 2025 and December 31, 2024, Chase Bank checking account had $ 1,363,185 and $ 5,216,354 , respectively, and the Chase Bank savings account had $ 20,215 and $ 20,021 , respectively. As of September 30, 2025 and December 31, 2024, SVB Bank checking account had $ 483,225 and $ 287,173 , respectively, and the SVB money market account had $ 10,000 and $ 10,000 , respectively. The Chase Bank and SVB Bank checking accounts were in excess of the FDIC limits for September 30, 2025. Redeemable Preferred Stock and Mezzanine Equity The Company’s one share of the Company’s Series A Senior Convertible Preferred Stock, par value $ 0.001 per share (the “Series A Preferred Stock”), in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 480 (“ASC 480”), is accounted for as mezzanine equity due to the redemption feature upon a deemed liquidation event: (i) a merger or consolidation, or (ii) the sale, lease, transfer or other disposition of substantially all the assets of the Company. The initial cash proceeds of $ 6,050,000 were allocated to the warrants to purchase shares of common stock (the “Series A Warrants”), and the residual proceeds were allocated to the Series A Preferred Stock. The subsequent cash proceeds of $ 1,053,000 were allocated to the Series A Warrants and the residual proceeds were allocated to the Series A Preferred Stock. The Series A Preferred Stock is classified as mezzanine equity in accordance with ASC 480. 6 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES (cont.) Fixed Asset Policy A capital asset is defined as a unit of property that has an economic useful life that extends beyond 12 months. Any items costing below the threshold or not fitting the definition of a capital asset will be expensed in the consolidated financial statements. All capital assets are recorded at historical cost as of the date acquired. Computer assets will be capitalized and Straight-Line depreciated over five years for financial statement purposes. Patent Amortization In connection with the HER2 Purchase Agreement (as defined below), the Company acquired the HER2 Assets (as defined below) from Ayala (as defined below), including the assignment by Ayala of a license agreement with the Trustees of the University of Pennsylvania, on April 9, 2025. The amortization expense is derived quarterly, based on the legal life of such assets on a straight-line basis. The three-month and nine-month amortization expense for the period ended September 30, 2025 was $ 124,243 and $ 236,062 , respectively. Patent & License Acquisition On April 9, 2025, pursuant to the terms of an Asset Purchase Agreement, dated as of January 28, 2025 (the “HER2 Purchase Agreement”), between the Company and Ayala Pharmaceuticals, Inc. (formerly Advaxis, Inc.) (“Ayala”), the Company completed the acquisition of the Lm -based immune-oncology programs and related intellectual property assets (the “HER2 Assets”) from Ayala, including the assignment by Ayala of a license agreement with the Trustees of the University of Pennsylvania. The purchase of the HER2 Assets is considered an asset acquisition under ASC 805. In connection for the purchase of the HER2 Assets, the Company agreed to assume certain specified liabilities and to pay an aggregate purchase price of $ 8,000,000 , with a fair value of $ 6,864,438 , consisting of (i) $ 400,000 to Ayala ($ 150,000 of which was transferred upon signing of the HER2 Purchase Agreement and the remainder on the closing date); (ii) $ 100,000 to a third party on behalf of Ayala on the closing date; and (iii) $ 7,500,000 worth of shares of common stock, or 4,774,637 shares based on the volume-weighted average price of the Company’s common stock over the 30 trading days immediately preceding the closing date of $ 1.5708 . The closing stock price on the April 9, 2025 closing date was $ 1.34 , resulting in a corresponding reduction in the acquisition value. The fair value of the purchase consideration is as follows: Cash $ 400,000 Legal fees paid on behalf of Ayala 66,424 Company common stock ( 4,774,637 shares at $ 1.34 per share) 6,398,014 Total Fair Value of Consideration Transfer for the Patent & License Acquisition. $ 6,864,438 The group of patents and the licensing is primarily focused on a set of patents for “Compositions and Methods for Evaluating Potency of Listeria-Based Immunotherapeutics,” which is the primary patent the Company utilizes in its treatments. This group of patents has an effective filing date on April 19, 2019. Based on such date, the group has an estimated remaining useful life of 14 years, with amortization expense of $ 236,062 and $ 0 , respectively, for the nine months ended September 30, 2025 and 2024. As of September 30, 2025, estimated amortization expenses related to the Company’s intangible assets for the years 2025 through 2039 and thereafter are as follows: Year 2025 $ 360,305 2026 496,972 2027 496,972 2028 496,972 2029 496,972 2030 and thereafter 4,516,245 Total $ 6,864,438 7 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES (cont.) Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the book values of the assets to future net undiscounted cash flows that the assets or the asset groups are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the estimated discounted future net cash flows arising from the assets or asset groups. No impairment losses on long-lived assets have been recorded for the periods ended September 30, 2025 and December 31, 2024. Deferred Offering Costs Deferred offering costs consist of capitalized underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related to the Company’s initial public offering and that were charged to stockholders’ equity upon the completion of such offering. As of September 30, 2025 and December 31, 2024, the Company did not have any capitalized deferred offering costs. Upon completion of the Company’s initial public offering on August 2, 2024, the deferred offering costs were charged to stockholders’ deficit. Research and Development Costs Research and development expenses are charged to operations as incurred. Research and development expenses include, among other things, salaries, costs of outside collaborators and outside services, and supplies. Revenue Recognition As of the date of incorporation, the Company adopted ASU 2014-09, Revenue from Contracts with Customers , and all subsequent amendments to the ASU (collectively, “ASC 606”), which (i) creates a single framework for recognizing revenue from contracts with customers that fall within its scope and (ii) revises when it is appropriate to recognize a gain (loss) from the transfer of nonfinancial assets. Stock-Based Compensation The Company, in accordance with ASC 718, employs the use of stock-based compensation. The compensation expense related to stock granted to employees and non-employees is measured at the grant date based on the estimated fair value of the award and is recognized on a straight-line basis over the requisite service period. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Short-term Leases For short-term leases, 12 months or less, we record rent expense. Our only lease currently meets this exemption and has been expensed. We have not renewed the current lease due to landlord restrictions; the ownership is renovating the premises. We have temporarily moved our primary office to 115 Pullman Crossing Road, Suite #103, in Grasonville, Maryland 21638. The space is the primary office of our Chief Financial Officer and is being provided rent free. In May 2024, we signed a month-to-month lease for use of general space with JLabs for $ 750 per month, primarily to use space for meetings in New York City and to have an office for our staff when they are visiting. The lease payment increased in January 1, 2025, with a monthly payment of $ 787.50 . 8 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES (cont.) Income taxes The Company accounts for income taxes using the asset-and-liability method in accordance with ASC 740, Income Taxes (“ASC 740”). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is recognized in the period that includes the enactment date. A valuation allowance is recorded if it is “more likely than not” that some portion or all of the deferred tax assets will not be realized in future periods. The Company follows the guidance in ASC Topic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition of tax benefits in the consolidated financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely than-not threshold are measured at the largest amount of tax benefit that is greater than 50 % likely of being realized upon ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the consolidated financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties related to tax positions in income tax expense. As of September 30, 2025 and December 31, 2024, the Company had no unrecognized uncertain income tax positions. Basic and Diluted Loss per Share The Company computes loss per share in accordance with ASC 260, Earnings per Share (“ASC 260”). ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the statements of operations. Basic EPS is computed by dividing the net loss available to common shareholders (numerator) by the weighted average number of common shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible notes payable using the if-converted method. Diluted EPS excludes all diluted potential shares if their effect is antidilutive. Below is a table listing all preferred stock and common stock equivalents. Common Stock Equivalents 9/30/2025 12/31/2024 Series A Convertible Preferred Stock 1,401,786 - Underwriter/Placement Agent Warrants 319,711 280,448 Inducement New Warrants 4,566,391 - Prepaid Common Stock Investors 937,500 - Ayala Prepaid Warrants 2,166,381 - Series A Warrants 1,337,947 1,512,500 Total 10,729,716 1,792,948 9 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES (cont.) Stockholder approval was obtained on April 9, 2025 for the issuance of the shares of common stock underlying the Company’s Series A Preferred Stock, which are being treated as Mezzanine Equity, and the Series A Warrants. The conversion price and exercise price, as applicable, of the Company’s Series A Preferred Stock and the Series A Warrants was automatically reset to $ 1.12 per share based on the volume weight average price of the Company’s common stock for the 10 trading days immediately preceding April 9, 2025, creating a conversion multiplier of 3.571429 of common shares to preferred shares. The number of non-converted shares of Series A Preferred Stock outstanding as of September 30, 2025 was 392,500 shares, with a 3.571429 conversion multiplier that equates to 1,401,786 shares of common stock. 112,000 shares of common stock underlying underwriter warrants issued in connection with our initial public offering were outstanding as of September 30, 2025. 207,711 shares of common stock underlying warrants issued to the placement agents in connection with our PIPE financing in December 2024 and January 2025 were outstanding as of September 30, 2025, totaling 319,711 shares of common stock underlying underwriter/placement agent warrants. Warrant holders who converted their existing warrants during the Company’s two warrant exercise and inducement offerings held open during the period from June 23 to July 10, 2025 and August 29 to September 1, 2025, respectively, received a new warrant at an exercise price of $ 3.00 per share. As of September 30, 2025, existing warrants to purchase an aggregate of 4,566,391 shares of common stock were exercised in exchange for new warrants to purchase an aggregate of 4,566,391 shares of common stock. A Warrant holder who pre-funded the conversion its existing warrants during the Company’s warrant exercise and inducement offerings during the period from August 29 to September 1, 2025 received an aggregate of 937,500 prepaid shares of common stock. As of September 30, 2025, Ayala continued to hold a prepaid warrant to purchase 2,166,381 shares of common stock. As of September 30, 2025, holders of Series A Warrants from the Company’s PIPE financing in December 2024 and January 2025 continued to hold Series A Warrants to purchase an aggregate of 1,337,947 shares of common stock. 1,720,054 shares of common stock underlying the Series A Warrants were outstanding as of September 30, 2025. Fair Value Measurements The Company applies ASC 820 Fair Value Measurement (“ASC 820”), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company’s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity’s own assumptions based on market data and the entity’s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances. The carrying value of the Company’s cash, accounts payable and accrued expenses are approximate fair value because of the short-term maturity of these financial instruments. The redemption feature of the debt instruments is recorded at fair value (See Note 3). Warrant liability is recorded at fair value. Currently, there is not an observable market for this type of derivative. Due to the lack of relevant and market reflective Level 1 and Level 2 inputs, the Company valued the warrant liability using Level 3 inputs, which require significant judgment and estimates on behalf of management in developing model assumptions. As of September 30, 2025 and December 31, 2024, the carrying value of the warrant liability in the aggregate was $ 0 and $ 1,971,975 , respectively (See Note 8). The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below: Level 1 — Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. Level 2 — Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. Level 3 — Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities. 10 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES (cont.) Warrant Liability The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and FASB ASC Topic 815, “Derivatives and Hedging” (“ASC 815”). The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. The warrants issued in connection with a Securities Purchase Agreements, dated as of December 24, 2024 (the “Purchase Agreement”), are recognized as a derivative liability in accordance with ASC 815. The Company recognizes the warrant instruments as a liability at fair value and adjusts the instruments to fair value at each reporting period. The liability is subject to re-measurement at each balance sheet date until exercised or reclassified, and any change in fair value is recognized in the Company’s consolidated statements of operations. The fair value of the warrants issued in connection with the Purchase Agreement were measured using a Binomial simulation model. The determination of the fair value of the warrant liability may be subject to change as more current information becomes available and accordingly the actual results could differ significantly. The derivative warrant liability is classified as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. Recent Accounting Pronouncements The Company has evaluated all recent accounting pronouncements and believes that none of them will have a material effect on the Company’s financial position, results of operations, or cash flows. NOTE 3 — RELATED PARTY TRANSACTIONS Accrued Payroll On September 30, 2025 and December 31, 2024, the Company had a payroll payable to the CEO of $ 0 and $ 8,871 , respectively, and related payroll taxes payable of $ 0 and $ 88,386 , respectively. During the period ended September 30, 2025 and December 31, 2024, the Company made advances on the payroll payable, and the CEO made repayments. The following summarizes activity in respect to payroll advances to the CEO: Balance December 31, 2023 $ 191,198 Advances during 2024 222,875 Repayment ( 414,073 ) Balance December 31, 2024 $ — Advances during 2025 122,852 Repayments 2025 ( 81,000 ) Balance September 30, 2025 $ 41,852 11 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 3 — RELATED PARTY TRANSACTIONS (cont.) In the second and third quarters of 2024, paychecks were issued to Paul Romness, CEO. The paychecks comprised the remaining balance of backpay, less all 2024 payroll advances. The payroll taxes were paid that were associated with the backpay and regular pay and are fully paid. The balance of accrued payroll for Mr. Romness on September 30, 2025 of $ 0 . All related party payroll advances shown as employee advances for Mr. Romness in the nine months ended September 30, 2025 are expected to be repaid in 2025. Related party payroll advances for Mr. Romness had a balance of $ 41,852 in the nine months ended September 30, 2025. All advances in the nine months ended September 30, 2024 were repaid in full as of December 31, 2024. Related Parties — Convertible Debt Ted Search and John Ciccio, collectively known as Mill River Partners LLC, are members of the Board and held convertible notes with face amounts of $ 0 and $ 0 as of September 30, 2025 and December 31, 2024, respectively. The convertible notes were converted into common stock upon consummation of the Company’s initial public offering on August 2, 2024. Related Party Accounting Fees The Company has a bill in accounts payable of $ 15,925 for the period ended September 30, 2025 and $ 26,765 for the period ended December 31, 2024 to Shore Accountants MD Inc., an outside accounting firm that handles payroll, bookkeeping and tax preparation, and is 100 % owned by Christopher Acevedo, the CFO. NOTE 4 — CONVERTIBLE DEBT Convertible Debt The Company’s convertible notes are separated into seven groups — A, B, C, D, E, F and BlinkBio — per the table below: September 30, 2025 December 31, 2024 Conversion Carrying Carrying Group Rate Maturity Collateral Rate Amount Amount A 10 % 10/31/2025 None 80 % - 87.5 % $ — $ — B 6 % 10/31/2025 None 80 % $ — $ — C 6 % 10/31/2025 None 80 % $ — $ — D 6 % 10/31/2025 None 50 % $ — $ — E 6 % 10/31/2025 None 50 % $ — $ — F 6 % 10/31/2025 None 50 % $ — $ — Blink Bio 10 % 3/15/2022 None 100 % $ — $ — The above convertible notes were all converted into common stock on August 2, 2024 upon consummation of the Company’s initial public offering. 12 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 4 — CONVERTIBLE DEBT (cont.) Group A Commencing in July 2018 through November 2021, the Company entered into an unsecured Subordinated Convertible Promissory Note Agreement (the “Agreements”) with certain lenders (together, the “Holders” or individually, the “Holder”). Interest on the unpaid principal balance accrues at a rate of 10 % per annum, computed on the basis of the actual number of days elapsed and a year of 365 days. Unless earlier converted into shares of Equity Securities, the principal and accrued interest will be due and payable by the Company on demand by the Holders at any time after the earlier of (i) the Maturity Date (as defined in each Agreement) and (ii) the closing of the Next Equity Financing (as defined below). The stated Maturity Date was extended on October 24, 2023, under the same terms, until October 31, 2024. The Notes will automatically convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note on the date of conversion of 80 – 87.5 % of the price paid per share for Equity Securities by the investors in the Next Equity Financing. Equity Securities refers to Company’s common stock or preferred stock and Next Equity Financing refers to the next sale (or series of related sales) by the Company of its equity securities from which the Company receives gross proceeds of not less than $ 3,000,000 (including the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of promissory notes) or $ 5,000,000 , depending upon the signed agreement terms. In the event that the Company raises aggregate additional cash proceeds of at least $ 3,000,000 or $ 5,000,000 through the sale of the Company’s equity securities, excluding the sales or conversions of Notes under the Agreement, the outstanding principal amount due will automatically, and without any action on part of the holder, be converted into fully paid and non-assessable units of the Company’s equity stock sold in such qualified financing at 12.5 % of the equity stock conversion price. The Company, at its option, may pay all accrued, but unpaid, interest and other charges in cash or by the issuance of additional equity stock at a rate of the applicable conversion price. The Company evaluated the Notes in accordance with ASC 480, Distinguishing Liabilities from Equity (“ASC 480”), and determined the Notes are considered share-settled debt and should be recorded as a liability. This conclusion was determined based on the debt providing the holder with a variable number of shares at settlement with an aggregate fair value equal to the debt instrument’s outstanding principal. The general measurement guidance in ASC 480 requires obligations that can be settled in shares with a fixed monetary value at settlement (e.g., share-settled debt) to be carried at fair value unless other accounting guidance specifies another measurement attribute. It has been determined that the appropriate guidance for share-settled debt is ASC 835. As a result, the Notes were recorded at the amortized cost. On August 2, 2024, the Company consummated its initial public offering, and the convertible notes, including accrued interest, converted into shares of the Company’s common stock. The convertible debt balance on September 30, 2025 and September 30, 2024 is summarized as follows: As of As of September 30, September 30, Debt A 2025 2024 Principal amount outstanding $ - $ 1,154,000 Less: discounts (issuance, redemptions) - ( 184,614 ) Amortization of discounts - 184,607 Carrying value - 1,153,993 Less Related Party Portion - ( 100,000 ) Convertible Notes – A $ - $ 1,053,993 The balance as of December 31, 2024 was $ 0 , as the notes converted into shares of common stock in connection with the closing of the Company’s initial public offering on August 2, 2024. 13 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 4 — CONVERTIBLE DEBT (cont.) Group B Commencing in May 2020, the Company entered into an unsecured Subordinated Convertible Promissory Note Agreement (the “Agreements”) with certain lenders (together, the “Holders” or individually, the “Holder”), pursuant to which the Company issued a Subordinated Convertible Promissory Note (individually the “Note” or together the “Notes”) to the Holders, principally the investors brought in by an investment bank. Interest on the unpaid principal balance accrues at a rate of 6 % per annum, computed on the basis of the actual number of days elapsed and a year of 365 days. Unless earlier converted into shares of Equity Securities, the principal and accrued interest will be due and payable by the Company on demand by the Holders at any time after the earlier of (i) the Maturity Date (as defined in each Agreement) and (ii) the closing of the Next Equity Financing (as defined below). The stated Maturity Date was extended on October 24, 2023, under the same terms, until October 31, 2024. The Notes will automatically convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note on the date of conversion of 80 % of the price paid per share for Equity Securities by the investors in the Next Equity Financing. Equity Securities refers to Company’s common stock or preferred stock and Next Equity Financing refers to the next sale (or series of related sales) by the Company of its equity securities from which the Company receives gross proceeds of not less than $ 10,000,000 (including the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of promissory notes). In the event that the Company raises aggregate additional cash proceeds of at least $ 10,000,000 through the sale of the Company’s equity securities, excluding the sales or conversions of Notes under the Agreement, the outstanding principal amount due will automatically, and without any action on part of the holder, be converted into fully paid and non-assessable units of the Company’s equity stock sold in such qualified financing at 12.5 % of the equity stock conversion price. The Company, at its option, may pay all accrued, but unpaid, interest and other charges in cash or by the issuance of additional equity stock at a rate of the applicable conversion price. The Company evaluated the Notes in accordance with ASC 480 and determined the Notes are considered share-settled debt and should be recorded as a liability. This conclusion was determined based on the debt providing the holder with a variable number of shares at settlement with an aggregate fair value equal to the debt instrument’s outstanding principal. The general measurement guidance in ASC 480 requires obligations that can be settled in shares with a fixed monetary value at settlement (e.g., share-settled debt) to be carried at fair value unless other accounting guidance specifies another measurement attribute. It has been determined that the appropriate guidance for share-settled debt is ASC 835. As a result, the Notes were recorded at the amortized cost. On August 2, 2024, the Company consummated its initial public offering, and the convertible notes, including accrued interest, converted into shares of the Company’s common stock. The convertible debt balance at September 30, 2025 and September 30, 2024 is summarized as follows: As of As of September 30, September 30, Debt B 2025 2024 Principal amount outstanding $ - $ 5,154,000 Less: discounts (issuance, redemptions, warrants) - ( 1,818,939 ) Amortization of discounts - 1,818,939 Carrying value $ - $ 5,154,000 The balance as of December 31, 2024 was $ 0 , as the notes converted into shares of common stock in connection with the closing of the Company’s initial public offering on August 2, 2024. 14 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 4 — CONVERTIBLE DEBT (cont.) Group C Commencing in July 2021, the Company entered into an unsecured Subordinated Convertible Promissory Note Agreement (the “Agreements”) with certain lenders (together, the “Holders” or individually, the “Holder”), pursuant to which the Company issued a Subordinated Convertible Promissory Note (individually the “Note” or together the “Notes”) to the Holders, principally the investors brought in by an investment bank. Interest on the unpaid principal balance accrues at a rate of 6 % per annum, computed on the basis of the actual number of days elapsed and a year of 365 days. Unless earlier converted into shares of Equity Securities, the principal and accrued interest will be due and payable by the Company on demand by the Holders at any time after the earlier of (i) the Maturity Date (as defined in each Agreement) and (ii) the closing of the Next Equity Financing (as defined below). The stated Maturity Date was extended on October 24, 2023, under the same terms, until October 31, 2024. The Notes will automatically convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note on the date of conversion of 80 % of the price paid per share for Equity Securities by the investors in the Next Equity Financing. Equity Securities refers to the Company’s common stock or preferred stock and Next Equity Financing refers to the next sale (or series of related sales) by the Company of its equity securities from which the Company receives gross proceeds of not less than $ 10,000,000 (including the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of promissory notes). In the event that the Company raises aggregate additional cash proceeds of at least $ 10,000,000 through the sale of the Company’s equity securities, excluding the sales or conversions of Notes under the Agreement, the outstanding principal amount due will automatically, and without any action on part of the holder, be converted into fully paid and non-assessable units of the Company’s equity stock sold in such qualified financing at 12.5 % of the equity stock conversion price. The Company, at its option, may pay all accrued, but unpaid, interest and other charges in cash or by the issuance of additional equity stock at a rate of the applicable conversion price. The Company evaluated the Notes in accordance with ASC 480, Distinguishing Liabilities from Equity (“ASC 480”), and determined the Notes are considered share-settled debt and should be recorded as a liability. This conclusion was determined based on the debt providing the holder with a variable number of shares at settlement with an aggregate fair value equal to the debt instrument’s outstanding principal. The general measurement guidance in ASC 480 requires obligations that can be settled in shares with a fixed monetary value at settlement (e.g., share-settled debt) to be carried at fair value unless other accounting guidance specifies another measurement attribute. It has been determined that the appropriate guidance for share-settled debt is ASC 835. As a result, the Notes were recorded at the amortized cost. On August 2, 2024, the Company consummated its initial public offering, and the convertible notes, including accrued interest, converted into shares of the Company’s common stock. The convertible debt balance on September 30, 2025 and September 30, 2024 is summarized as follows: As of As of September 30, September 30, Debt C 2025 2024 Principal amount outstanding $ - $ 3,945,020 Less: discounts (issuance, redemptions, warrants) - ( 1,088,223 ) Amortization of discounts - 1,088,223 Carrying value $ - $ 3,945,020 The balance as of December 31, 2024 was $ 0 , as the notes converted into shares of common stock in connection with the closing of the Company’s initial public offering on August 2, 2024. 15 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 4 — CONVERTIBLE DEBT (cont.) Group D Commencing in November 2022, the Company entered into an unsecured Subordinated Convertible Promissory Note Agreement (the “Agreements”) with certain lenders (together, the “Holders” or individually, the “Holder”), pursuant to which the Company issued a Subordinated Convertible Promissory Note (individually the “Note” or together the “Notes”) to the Holders, principally the Investors brought in by an investment bank. Interest on the unpaid principal balance accrues at a rate of 6 % per annum, computed on the basis of the actual number of days elapsed and a year of 365 days. Unless earlier converted into shares of Equity Securities, the principal and accrued interest will be due and payable by the Company on demand by the Holders at any time after the earlier of (i) the Maturity Date (as defined in each Agreement) and (ii) the closing of the Next Equity Financing (as defined below). The stated Maturity Date was extended on October 24, 2023, under the same terms, until October 31, 2024. The Notes will automatically convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note on the date of conversion of 50 % of the price paid per share for Equity Securities by the investors in the Next Equity Financing. Equity Securities refers to Company’s common stock or preferred stock and Next Equity Financing refers to the next sale (or series of related sales) by the Company of its equity securities from which the Company receives gross proceeds of not less than $ 10,000,000 (including the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of promissory notes). In the event that the Company raises aggregate additional cash proceeds of at least $ 10,000,000 through the sale of the Company’s equity securities, excluding the sales or conversions of Notes under the Agreement, the outstanding principal amount due will automatically, and without any action on part of the holder, be converted into fully paid and non-assessable units of the Company’s equity stock sold in such qualified financing at 50 % of the equity stock conversion price. In connection with the Group D Convertible Notes, the Company agreed to issue an additional 125,000 shares of common stock to the Group D Holders, prorated based on such Holder’s investment amount, as an inducement for their investment in the Group D Convertible Notes. The Company, at its option, may pay all accrued, but unpaid, interest and other charges in cash or by the issuance of additional equity stock at a rate of the applicable conversion price. The Company evaluated the Notes in accordance with ASC 480 and determined the Notes are considered share-settled debt and should be recorded as a liability. This conclusion was determined based on the debt providing the holder with a variable number of shares at settlement with an aggregate fair value equal to the debt instrument’s outstanding principal. The general measurement guidance in ASC 480 requires obligations that can be settled in shares with a fixed monetary value at settlement (e.g., share-settled debt) to be carried at fair value unless other accounting guidance specifies another measurement attribute. It has been determined that the appropriate guidance for share-settled debt is ASC 835. As a result, the Notes were recorded at the amortized cost. On August 2, 2024, the Company consummated its initial public offering, and the convertible notes, including accrued interest, converted into shares of the Company’s common stock. 16 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 4 — CONVERTIBLE DEBT (cont.) The convertible debt balance at September 30, 2025 and September 30, 2024 is summarized as follows: As of As of September 30, September 30, Debt D 2025 2024 Principal amount outstanding $ - $ 2,000,000 Less: discounts (issuance, redemptions, warrants) - ( 1,864,654 ) Amortization of discounts - 1,864,654 Carrying value $ - $ 2,000,000 The balance as of December 31, 2024 was $ 0 , as the notes converted into shares of common stock in connection with the closing of the Company’s initial public offering on August 2, 2024. Group E Commencing in February 2023, the Company entered into an unsecured Subordinated Convertible Promissory Note Agreement (the “Agreements”) with certain lenders (together, the “Holders” or individually, the “Holder”), pursuant to which the Company issued a Subordinated Convertible Promissory Note (individually the “Note” or together the “Notes”) to the Holders, principally the investors brought in by an investment bank. Interest on the unpaid principal balance accrues at a rate of 6 % per annum, computed on the basis of the actual number of days elapsed and a year of 365 days. Unless earlier converted into shares of Equity Securities, the principal and accrued interest will be due and payable by the Company on demand by the Holders at any time after the earlier of (i) the Maturity Date (as defined in each Agreement) and (ii) the closing of the Next Equity Financing (as defined below). The stated Maturity Date was extended on October 24, 2023, under the same terms, until October 31, 2024. The Notes will automatically convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note on the date of conversion of 50 % of the price paid per share for Equity Securities by the investors in the Next Equity Financing. Equity Securities refers to Company’s common stock or preferred stock and Next Equity Financing refers to the next sale (or series of related sales) by the Company of its equity securities from which the Company receives gross proceeds of not less than $ 10,000,000 (including the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of promissory notes). In the event that the Company raises aggregate additional cash proceeds of at least $ 10,000,000 through the sale of the Company’s equity securities, excluding the sales or conversions of Notes under the Agreement, the outstanding principal amount due will automatically, and without any action on part of the holder, be converted into fully paid and non-assessable units of the Company’s equity stock sold in such qualified financing at 50 % of the equity stock conversion price. In connection with the Group E Convertible Notes, the Company agreed to issue an additional 68,750 shares of common stock to the Group E Holders, prorated based on such Holder’s investment amount, as an inducement for their investment in the Group E Convertible Notes. The Company, at its option, may pay all accrued, but unpaid, interest and other charges in cash or by the issuance of additional equity stock at a rate of the applicable conversion price. The Company evaluated the Notes in accordance with ASC 480 and determined the Notes are considered share-settled debt and should be recorded as a liability. This conclusion was determined based on the debt providing the holder with a variable number of shares at settlement with an aggregate fair value equal to the debt instrument’s outstanding principal. The general measurement guidance in ASC 480 requires obligations that can be settled in shares with a fixed monetary value at settlement (e.g., share-settled debt) to be carried at fair value unless other accounting guidance specifies another measurement attribute. It has been determined that the appropriate guidance for share-settled debt is ASC 835. As a result, the Notes were recorded at the amortized cost. On August 2, 2024, the Company consummated its initial public offering, and the convertible notes, including accrued interest, converted into shares of the Company’s common stock. 17 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 4 — CONVERTIBLE DEBT (cont.) The convertible debt balance at September 30, 2025 and September 30, 2024 is summarized as follows: As of As of September 30, September 30, Debt E 2025 2024 Principal amount outstanding $ - $ 1,100,000 Less: discounts (issuance, redemptions, warrants) - ( 550,000 ) Amortization of discounts - 550,000 Carrying value - 1,100,000 Less related party portion - ( 50,000 ) Convertible Notes – E $ - $ 1,050,000 The balance as of December 31, 2024 was $ 0 , as the notes converted into shares of common stock in connection with the closing of the Company’s initial public offering on August 2, 2024. Group F Commencing in June 2023, the Company entered into an unsecured Subordinated Convertible Promissory Note Agreement (the “Agreements”) with certain lenders (together, the “Holders” or individually, the “Holder”), pursuant to which the Company issued a Subordinated Convertible Promissory Note (individually the “Note” or together the “Notes”) to the Holders, principally the investors brought in by an investment bank. Interest on the unpaid principal balance accrues at a rate of 6 % per annum, computed on the basis of the actual number of days elapsed and a year of 365 days. Unless earlier converted into shares of Equity Securities, the principal and accrued interest will be due and payable by the Company on demand by the Holders at any time after the earlier of (i) the Maturity Date (as defined in each Agreement) and (ii) the closing of the Next Equity Financing (as defined below). The stated Maturity Date was extended on October 24, 2023, under the same terms, until October 31, 2024. The Notes will automatically convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note on the date of conversion of 50 % of the price paid per share for Equity Securities by the investors in the Next Equity Financing. Equity Securities refers to Company’s common stock or preferred stock and Next Equity Financing refers to the next sale (or series of related sales) by the Company of its equity securities from which the Company receives gross proceeds of not less than $ 10,000,000 (including the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of promissory notes). In the event that the Company raises aggregate additional cash proceeds of at least $ 10,000,000 through the sale of the Company’s equity securities, excluding the sales or conversions of Notes under the Agreement, the outstanding principal amount due will automatically, and without any action on part of the holder, be converted into fully paid and non-assessable units of the Company’s equity stock sold in such qualified financing at 50 % of the equity stock conversion price. In connection with the Group F Convertible Notes, the Company agreed to issue an additional 214,594 shares of common stock to the Group F Holders, prorated based on such Holder’s investment amount, as an inducement for their investment in the Group F Convertible Notes. The Company, at its option, may pay all accrued, but unpaid, interest and other charges in cash or by the issuance of additional equity stock at a rate of the applicable conversion price. The Company evaluated the Notes in accordance with ASC 480, Distinguishing Liabilities from Equity (“ASC 480”), and determined the Notes are considered share-settled debt and should be recorded as a liability. This conclusion was determined based on the debt providing the holder with a variable number of shares at settlement with an aggregate fair value equal to the debt instrument’s outstanding principal. The general measurement guidance in ASC 480 requires obligations that can be settled in shares with a fixed monetary value at settlement (e.g., share-settled debt) to be carried at fair value unless other accounting guidance specifies another measurement attribute. It has been determined that the appropriate guidance for share-settled debt is ASC 835. As a result, the Notes were recorded at the amortized cost. On August 2, 2024, the Company consummated its initial public offering, and the convertible notes, including accrued interest, converted into shares of the Company’s common stock. 18 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 4 — CONVERTIBLE DEBT (cont.) The convertible debt balance at September 30, 2025 and September 30, 2024 is summarized as follows: As of As of September 30, September 30, Debt F 2025 2024 Principal amount outstanding $ - $ 3,433,500 Less: discounts (issuance, redemptions, warrants) - ( 1,212,718 ) Amortization of discounts - 874,436 Carrying value $ - $ 3,095,218 The balance as of December 31, 2024 was $ 0 , as the notes converted into shares of common stock in connection with the closing of the Company’s initial public offering on August 2, 2024. Redemption Liability The fair value of the redemption liability is calculated under Level 3 of the fair value hierarchy, is determined based upon a Probability-Weighted of Expected Returns Model (“PWERM”). This PWERM was determined to be the most appropriate method of estimating the value of possible redemption or conversion outcomes over time, since the Company did not enter into a priced equity round through June 30, 2024. The fair value of the redemption liability is calculated using the initial value of the convertible note less the debt discount rate of 12.5 % in Group A, 20 % in Groups B and C, and 50 % in Groups D, E and F. The redemption liability is then amortized over the remaining life of the note, utilizing the interest rates of 10 % and 6 % respectively for the groups. The life of each note in Group A is for a set period of 3 years, and is variable in Groups B, C, D, E and F with a range of 12 months to 3 years. The Company retains the option to negotiate an extended maturity date for Groups B, C, D, E and F. The new embedded redemption values were $ 0 for the nine months ended September 30, 2025 and the year ended December 31, 2024. On August 2, 2024, the Company consummated its initial public offering, and the convertible notes, including accrued interest, converted into shares of the Company’s common stock. The redemption liability was closed to stockholders’ equity on such date. Fees Associated with Convertible Debt Raise The fees associated with the convertible debt raise are legal and investment fees associated with the issuance of the convertible notes for Groups A, B, C, and D. There were no related parties who received these fees. The fees are amortized over the life of the convertible note utilizing an interest rate of 10 % for Group A and 6 % for Groups B, C, and D. Make-whole liability — Shares due Noble Capital In March 2020, the Company signed a new advisory agreement with Noble Capital, in lieu of cash remuneration and the company agreed to issue 4 % of the Company’s shares, with an anti-dilution clause. The make-whole liability represents the shares earned for the anti-dilution of their stock position over 2020 and 2021. The 2021 year-end had the Company owning an aggregate of 233,202 shares valued in the amount of $ 408,413 , after issuing 200,000 shares in 2020. In 2021, the Company recorded an associated expense to advisory fees of $ 152,482 to recognize the share value earned on the anti-dilution compensation in 2021. In 2022, the Company set aside 70,624 shares to satisfy the anti-dilution clause. In 2022, the Company recorded an associated expense to advisory fees of $ 282,496 to recognize the share value earned on the anti-dilution compensation in the 2022. 19 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 4 — CONVERTIBLE DEBT (cont.) On July 1, 2023, the make-whole liability for Noble Capital was determined to be contractually nullified. The Company unwound the liability, and it is reflected in our Statement of Stockholders’ Deficit. Noble Capital and the Company settled on various investment fees in dispute, as well as the shares of the Company’s common stock related to the anti-dilution clause that expired in September 2024. Noble Capital was awarded 320,033 shares of common stock and $ 50,000 in cash. Make-whole liability — Shares Officers & Directors In January 2023, 350,000 shares of Class A common stock were issued to officers, key employees, key advisors and directors, leaving 20,000 shares in the balance to be issued to Joacim Borg, a former director with a value of $ 80,000 . On March 1, 2023, the Company hired Alan Musso, former CFO, and, as part of his compensation contract, he was awarded 12,500 shares of common stock with a value of $ 4.00 per share, the $ 50,000 in compensation of which is reflected in the make-whole stock liability. Alan resigned on June 30, 2023, and Christopher Acevedo, current CFO, took his position. Mr. Acevedo was awarded the balance of Mr. Musso’s shares upon the successful initial public offering. The Company’s make-whole share liability is summarized in the table below as of September 30, 2024. Name Position # Shares Value Date Earned Alan Musso Former CFO 3,125 $ 12,500 March 1, 2023 Christopher Acevedo Current CFO 9,375 37,500 Upon IPO Joacim Borg Former Director 20,000 80,000 July 1, 2022 32,500 $ 130,000 The Company issued all of the make-whole shares due to the director and officers in October 2024, and therefore, the current balance due for each of the periods ended September 30, 2025 and December 31, 2024 was $ 0 . 20 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 4 — CONVERTIBLE DEBT (cont.) Warrants for Placement Agent — Noble Capital In March 2020, the Company signed a new advisory agreement with Noble Capital, in lieu of cash remuneration it was provided a 10 % warrant fee, in addition to cash remuneration on debt raises from Noble procured investments. The terms of the warrants are five years at an exercise price that equates to the average price the convertible debt holders paid in each debt raise round. The number of warrants earned in 2020 was 248,855 valued at $ 248,855 . The number of warrants earned in 2021 was 213,782 , valued at $ 427,564 . The total warrants earned as of December 31, 2022 was 162,644 , valued at $ 325,288 . No warrants were earned from 2023 to December 31, 2024. Warrants earned in 2022, 2021 and 2020 have been accounted for as a discount to the associated convertible debt with the discounts amortized over the term of the related debt. The Debt Discount Accretion expense in warrants in the nine months ended September 30, 2025 was $ 0 and in the nine months ended September 30, 2024 was $ 49,840 . The total unamortized discount of those warrants was $ 0 and $ 0 as of September 30, 2025 and December 31, 2024, respectively. Warrant holders from Noble Capital exercised their warrants in cashless exercise for an aggregate of 116,313 shares of common stock out of the aggregate 621,691 shares underlying warrants held by such holders in September 2024 and exercised their remaining warrants in a reduced cashless transaction for an aggregate of 294,977 shares of common stock in December 2024. Warrants for Underwriter and Placement Agents — Brookline Capital Markets and Ceros Financial Services, Inc. On August 2, 2024, the Company issued a warrant to Brookline Capital Markets to purchase 112,000 shares of the Company’s common stock, pursuant to an underwriting agreement entered into between the Company and Brookline. The warrant is exercisable 180 days after July 31, 2024, terminates on July 31, 2029, and has an exercise price of $ 4.40 per share. On December 24, 2024, the Company entered into the Purchase Agreement and, in connection therewith, Brookline earned warrants initially exercisable into an aggregate of 39,918 shares at an initial exercise price of $ 4.40 per share, which were subsequently adjusted to 156,821 shares at an exercise price of $ 1.12 per share, and subject to further adjustment as set forth therein. The warrants are exercisable by the holder for a period of five years from April 9, 2025. As of September 30, 2025, warrants to purchase an aggregate of 156,821 shares were outstanding. In connection with the Purchase Agreement, Ceros earned warrants initially exercisable into an aggregate of 13,951 shares at an initial exercise price of $ 4.40 per share, which were subsequently adjusted to 54,807 shares at an exercise price of $ 1.12 per share, and subject to further adjustment as set forth therein. The warrants are exercisable by the holder for a period of five years from April 9, 2025. As of September 30, 2025, warrants to purchase an aggregate of 52,872 shares were outstanding. Short-Term Loan An investor lent the Company $ 100,000 on March 7, 2024. The note is a demand note, carrying interest at 8 % and was used for working capital purposes. An investor lent the Company $ 150,000 on June 28, 2024. The note is a demand note, carrying interest at 8 % and was also used for working capital purposes. The Company repaid these loans, including accrued interest thereon, in August 2024. 21 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 5 — TEDCO GRANT In May of 2021, the Company received the first of two tranches from TEDCO’s Rural & Underserved Business Recovery from Impact of COVID-19 (RUBRIC) Grant in the amount of $ 50,000 . A second tranche of $ 50,000 was received in October 2021 for a total reimbursable grant amount of $ 100,000 . The Company is obligated to report on and pay to TEDCO 3% of their quarterly revenues for a five-year period following the reward date. Income from grants and investments are not considered revenues. Royalties due to TEDCO are capped at 150 % of the amount of the award or $ 150,000 total. The Company has the option to eliminate the quarterly royalty obligation by making an advance payment prior to the end of the five-year period, in which case, the Company will receive a 10 % reduction of the royalty cap percentage for each year prior to the expiration of the five-year reimbursement period that the grant is repaid in full. If the Company ceases to meet eligibility requirements the reimbursement obligation will become due to TEDCO immediately; however, the discount for meeting the obligation will still apply. NOTE 6 — COMMITMENTS AND CONTINGENCIES Employee Commitments There are no employee commitments as the Company operates on an at-will employment basis. Rental Agreement The Company has rented, on a month-to-month basis, a virtual office at JLabs in New York, New York (owned by Johnson & Johnson). The current rent for Johnson and Johnson is $ 787.50 per month, with rent expense for the nine months ended September 30, 2025 and 2024 of $ 5,513 and $ 1,750 , respectively. License Obligation and Manufacturing Agreements Advaxis (now Ayala) The Company entered into an exclusive license agreement with Advaxis, Inc. in September 2018, as amended, pursuant to which it acquired the right to develop and commercialize Advaxis HER2 Construct, the Company’s product candidate and the use of Advaxis HER2 Construct patents. Per the agreement, all milestone payments were non-creditable and non-refundable and were due and payable upon the occurrence of the corresponding milestone event. For clarity, each milestone payment was payable only once. As of December 31, 2020, the Funding Milestone had been achieved and payment in full was made in January 2021. As of May 2021, the second milestone had been completed and paid. For the nine months ended September 30, 2025 and for the year ended December 31, 2024, no payments were made. A $ 400,000 payment was made to Ayala, together with payment of stock consideration, in connection with the Company’s purchase of the HER2 Assets on April 9, 2025, terminating this license agreement. 22 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 6 — COMMITMENTS AND CONTINGENCIES (cont.) The milestone events and financial terms were as follows: Milestone Amount 1. OST has secured funding of at least Two Million Three Hundred Thirty-Seven Thousand Five Hundred US Dollars ($2,337,500), in the aggregate (The Funding Milestone) (paid) License Commencement Payment $ 1,550,000 2. The earlier to occur of: (A) OST having secured at least Eight Million US Dollars, in the aggregate or (B) Completion of the first Clinical Trial (with “Completion” meaning that the final patient has enrolled in first Clinical Trial) (paid) $ 1,375,000 3. The earlier to occur of: (A) receipt of Regulatory Approval from the FDA for the First Indication of the first Licensed Product or (B) Initiation of the first Registrational Trial of the first Licensed Product in the Field $ 5,000,000 4. Cumulative Net Sales of all Licensed Products in excess of Twenty Million US Dollars ($20,000,000) $ 1,500,000 5. Cumulative Net Sales of all Licensed Products in excess of Fifty Million US Dollars ($50,000,000) Cumulative Net Sales of all Licensed Products in ex $ 5,000,000 6. Cumulative Net Sales of all Licensed Products in excess of One Hundred Million US Dollars ($100,000,000) $ 10,000,000 All milestone payments were non-creditable and non-refundable and were due and payable upon the occurrence of the corresponding date or milestone, regardless of any failure by the Company to provide the notice required by Section 6.4a of the licensing agreement. For clarity, each milestone payment was payable only once. As of December 31, 2020, the first milestone had been achieved. As of January 7, 2021, the license commencement payment was paid in full. As of May 21, 2021, the second milestone had been completed and paid in full. Additionally, on an aggregate basis across all licensed products during the royalty term, the Company agreed to pay quarterly to Advaxis royalties on net sales of licensed products, royalty rates range from a percentage in the high single digits to low double digits. No royalties were payable in the nine months ended September 30, 2025 and for the year ended December 31, 2024. In connection with the purchase of the HER2 Assets, the license agreement is terminated, and no further royalties to Ayala will be due. BlinkBio In July 2020, the Company entered into a Licensing Agreement with BlinkBio, Inc., to utilize their proprietary technology. As of August 2020, the $ 300,000 License fee was fully paid and recorded in license expense. These payments have been recorded in the Licensing expenses of the accompanying statement of operations. No payments were due or made in 2024 or the nine months ended September 30, 2025. The Company is studying the drug and is pursuing science that will lead to a toxicology study; however, the work is in its early stages. A payment schedule for future milestones is summarized below. Milestone Bearing Event Milestone Payment 1. License Fee to utilize proprietary technology (paid) $ 300,000 + $ 2.4 million Convertible Note 2. Commencement of a toxicology study commented pursuant to Good Laboratory Practices (per 21 CFR Part 58) such that any resulting positive data would be admissible to applicable Regulatory Authorities to support an IND (commonly referred to as “GLP-Tox”) $ 375,000 3. Completion of a Phase I Clinical Trial $ 1,500,000 4. Completion of a Phase II Clinical Trial $ 2,500,000 5. Filing of an NDA, BLA or MAA registration (or the equivalent in any other territory around the world) $ 6,000,000 6. Regulatory Approval in the first of the United States, within the EU or within the UK $ 12,000,000 23 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 6 — COMMITMENTS AND CONTINGENCIES (cont.) The Company will make the cash payments set forth in the table above by wire transfer of immediately available funds, to BlinkBio within 30 days of the occurrence of each milestone set forth with respect to the first Product to attain each such milestone, except that the first Milestone above will apply with respect to The Company’s first product candidate. During the Royalty Term, the Company will pay BlinkBio a royalty of 6 % on Net Sales on a Product-by-Product and country-by-country basis during the Royalty Term, in a country in which no Valid Claim Covers the manufacture, use, or sale of a Product, the royalty on Net Sales of such Product in such country will be reduced to 3 %. No royalties were due in the nine months ended September 30, 2025 and for the year ended December 31, 2024. For the avoidance of doubt, each milestone payment will be payable only once, and the aggregate amount of Milestone payments payable hereunder will not exceed $ 22,375,000 . A Milestone may be achieved by the Company or a Commercial Sublicensee. George Clinical Inc. In June 2020, the Company entered into a Research Service Agreement, as amended, with George Clinical Inc., to use their clinical research services for the Company’s study: “ An Open Label, Phase 2 Study of Maintenance Therapy with OST-HER2 after Resection of Recurrent Osteosarcoma ”. Under the terms of the agreement, the Company is required to pay to George Clinical certain fees described in the fee schedule below. The total budget under the agreement is approximately $ 2,436,928 . For the nine months ended September 30, 2025 and 2024, the total research and development expenses recorded in the statement of operations was $ 0 and $ 86,687 , respectively. The fee schedule for certain fees and corresponding payment amounts is set forth below. George Clinical Payment Schedule Payment Amount 1. Service Fee Advance (paid) $ 49,989 2. Service Fee Advance of $212,335 minus the amount already paid, plus PTC Fee Advance of $31,325 (paid) $ 193,671 3. Statistics Fees – 35% on Electronic Data Capture (EDC) Go Live Date $ 47,740 4. Statistics Fees – 35% on Development of SAP tables $ 47,740 5. Statistics Fees – 30% on Final Analysis $ 40,920 6. Service Fees – Remainder Due Split monthly over course of study George Clinical will track and invoice the Company for the number of task units completed and pass-through costs will be invoiced each month in arrears based on actual costs without mark-up. The PTC Advance Fee will be used to offset final pass-through fees payable. As of September 30, 2025, the balance due to George Clinical was $ 0 , and the services agreement has terminated on its terms. Biolacuna Ltd The Company has contracted with Biolacuna Ltd, a global life sciences advisory firm, to assist with the following agencies requirements to register OST-HER2 and gain approval of its use in the respective regions: ● European Medicines Agency (EMA, Europe); ● Medicines Evaluation Board (MEB, Netherlands); ● Medicines and Healthcare products Regulatory Agency (MHRA, United Kingdom); and ● U.S. Food and Drug Administration (FDA, United States). For the nine months ended September 30, 2025, the Company has paid $ 2,397,131 in consulting fees, with accounts payable as of September 30, 2025 of $ 2,022,496 . The contract with Biolacuna is estimated to exceed $ 5.2 million in 2025. 24 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 6 — COMMITMENTS AND CONTINGENCIES (cont.) Trustees for the University of Pennsylvania In connection with the purchase of the HER2 Assets, the Company was assigned by Ayala a licensing agreement with the Trustees of the University of Pennsylvania for HER2 Constructs, the Company’s lead product candidate, and the use of Advaxis HER2 Constructs. The Company has agreed to pay an annual fee to the Trustees of the University of Pennsylvania. In April 2025, the Company paid a fee of $ 266,317 for the nine months ended September 30, 2025. In addition, the Company has agreed to pay a royalty of 1.5 % of net sales related to: ● OST-HER2-related sales; ● ADXS-503-related sales; ● ADXS-504-related sales; and ● Sales related to any new immunotherapy drug candidates created from the Lm platform during the term of such license. Legal Proceedings From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business. Any of these claims could subject the Company to costly legal expenses and, while management generally believes that there will be adequate insurance to cover different liabilities at such time the Company becomes a public company and commences clinical trials, the Company’s future insurance carriers may deny coverage or policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company’s reputation and business. The Company is currently not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, could have a material adverse effect on the Company’s results of operations or financial position. The Company participated in an arbitration hearing that ended on November 7, 2025 for a claim brought by its former investment advisor. The claim is for underwriter compensation for the Company’s initial public offering in August 2024 along with any Company equity offerings that continue for a period of 12 months thereafter. The Company awaits a formal ruling by the arbitrators, which could take two to three months. The Company expects a resolution in February 2026. NOTE 7 — EQUITY Common Stock In 2021, the Company split common stock into two classes with fifty million shares of Class A common stock, $ 0.001 par value per share (“Class A Common Stock”) designated and twenty million shares of Class B common stock, $ 0.001 par value per share (“Class B Common Stock”). On February 9, 2024, the Company changed the name of the Class A Common Stock and Class B Common Stock to combine into the name common stock, with 50,000,000 shares authorized. As of September 30, 2025 and December 31, 2024, the Company had 33,269,981 and 20,869,908 shares of common stock outstanding, respectively. Common stock has voting rights . On August 2, 2024, the Company consummated its initial public offering and sold 1.6 million shares of common stock at a price of $ 4.00 per share. Concurrent with this consummation, all outstanding convertible notes, including accrued interest thereon, automatically converted into approximately 13.2 million shares of common stock, at conversion prices ranging from $ 0.39 per share to $ 2.59 per share, after applying share discounts ranging from 50 % to 87.5 % and valuation ceilings ranging from $ 5 million to $ 50 million, as applicable. During the three months ended March 31, 2025, the Company issued (i) 157,407 shares of common stock in connection with its equity line of credit, (ii) 300,000 shares of common stock to a scientific and technical advisor in exchange for scientific and technical services, which will be amortized over a 12-month period with the remaining balance in prepaid expenses, and (iii) 20,000 shares of common stock to an advisor in exchange for services. During the three months ended June 30, 2025, the Company issued (i) 3,962,129 shares of common stock in connection with conversions of Series A Preferred Stock, (ii) 2,164,215 shares of common stock in connection with the purchase of the HER2 Assets, (iii) 2,166,381 pre-funded warrants in connection with the purchase of the HER2 Assets, (iv) 10,000 shares of common stock to an advisor in exchange for services and (v) 2,181,257 shares of common stock in connection with the Company’s warrant exercise inducement and exchange offering. During the three months ended September 30, 2025, the Company issued (i) 977,679 shares of common stock in connection with conversions of Series A Preferred Stock, (ii) 2,507,386 shares of common stock in connection with the Company’s warrant exercise inducement and exchange offering and (iii) 120,000 shares of common stock to an advisor in exchange for services. Additionally, the Company received $ 1,050,000 in gross proceeds, which was recorded as additional paid-in capital, from the exercise of Series A Warrants to purchase 937,500 shares of common stock, which were issued subsequent to September 30, 2025. 25 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 7 — EQUITY (cont.) During two warrant exercise inducement period from June 23 to July 10, 2025 and August 29 to September 1, 2025, all warrant holders of the Series A Warrants that exercised such warrants at the then-current exercise price of $ 1.12 per share received a new warrant to purchase a number of shares of common stock equal to the number of shares exercised. Such new warrants have an exercise price of $ 3.00 per share and a term of exercise of five years from the date of issuance and are immediately exercisable. Preferred Stock In 2021, 5,000,000 shares of Preferred Stock were authorized, 1,400,000 were designated as Series A Preferred Stock, with 1,302,082 shares issued of Series A Preferred Stock. Series A Preferred Stock has 5 % cumulative coupon and liquidation priority above all shares of the Company’s common stock. The coupon dividends are computed at 5 % of the principal per annum and are recorded monthly. On February 9, 2024, the Series A Preferred Stock outstanding was converted to common stock on a one common share for every two preferred shares basis upon the filing of the Company’s third amended and restate certificate of incorporation. Effective February 9, 2024, the company had five million shares of authorized Preferred Stock, none of which were outstanding. The dividend due for the nine months ended September 30, 2025 and for the year ended December 31, 2024 was $ 0 and $ 31,250 , respectively, for a total accrued dividend payable at September 30, 2025 of $ 375,000 . The Preferred Stock has the following rights and privileges: Voting — Votes together with the common stock on all matters on an as-converted basis. Approval of a majority of the New Preferred Stock voting as a separate class will be required to, among other things: (i) adversely change rights of the New Preferred Stock, (ii) change the authorized number of shares of New Preferred Stock. Conversion — Each share of New Preferred Stock is convertible into one share of common stock (subject to proportional adjustments for stock splits, stock dividends and the like) at any time at the option of the holder. Conversion ratio will be subject to adjustment on a broad-based, weighted average basis in the event of subsequent issuances at a price less than the original issue price (as adjusted) subject to customary exceptions. The conversion into common stock occurred on February 9, 2024. Liquidation — One times the original issue price of the New Preferred Stock plus declared but unpaid dividends on each share of New Preferred Stock (or, if greater, the amount that the New Preferred Stock would receive on an as-converted basis) will be paid first on each share of New Preferred Stock, and the balance of proceeds to be paid to common stock. A merger, reorganization, or similar transaction (including a sale, exclusive license or other disposition of all or substantially all of the assets of the Company or its subsidiaries) will be treated as a liquidation, thereby triggering payment of the liquidation preference described above. For the avoidance of doubt, the liquidation preference is intended to provide the Investor (and its permitted assigns) with an aggregate liquidation payment of $ 2,500,000 . 26 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 7 — EQUITY (cont.) Stock Options The following are the common stock options issued to employees and consultants for services during the nine months ended September 30, 2025: Common Stock Options Shares Weighted Average Exercise Price Weighted Average Remaining Years Intrinsic Value Outstanding at January 1, 2025 2,866,750 $ 1.86 3.92 - Granted - - - - Forfeited - - - - Exercised - - - - Outstanding at September 30, 2025 2,866,750 $ 1.86 3.92 - Exercisable at September 30, 2025 - - - - The fair value of the options granted during the year ended December 31, 2024 was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions: December 31, 2024 Volatility (based on peer companies) 106 % Risk Free Interest Rate 4.09 Dividends None Estimated Life in years 2.95 During the nine months ended September 30, 2025 and 2024, the Company recognized share-based compensation expense of $ 2,661,396 and $0 , respectively, related to common stock options. The Company expects to recognize additional compensation expense of $ 582,731 in fourth quarter of 2025 related to these common stock options assuming all awards will vest. NOTE 8 — REDEEMABLE PREFERRED STOCK, MEZZAININE EQUITY AND WARRANT LIABILITY Securities Purchase Agreement On December 24, 2024, the Company entered into the Purchase Agreement with various institutional and accredited investors. The Company completed the initial closing on December 31, 2024 and sold an aggregate of 1,512,500 immediately separable units (the “Units”), each Unit consisting of (i) one share of the Company’s Series A Preferred Stock, and (ii) a Warrant to purchase one share of common stock, at a price per Unit of $ 4.00 . The Warrant has an exercise price of $ 4.40 per share, subject to adjustment therein, and a term of five years from the date stockholder approval of the common stock issuances contemplated by the Purchase Agreement is obtained. The gross proceeds from the initial closing to the Company, before deducting transaction fees and other estimated expenses, was $ 6,050,000 . On January 14, 2025 the Company sold and issued an additional 263,250 Units. The gross proceeds from the second closing to the Company, before deducting transaction fees and other estimated expenses, was $ 1,053,000 . Based on the terms of the Series A Preferred Stock and the Company’s Certificate of Designation, and in accordance with ASC 480, the Series A Preferred Stock is accounted for as mezzanine equity due to the redemption feature upon a deemed liquidation event: (i) a merger or consolidation, or (ii) the sale, lease, transfer or other disposition of substantially all the assets of the Company. $ 1,971,975 of the initial cash proceeds of $ 6,050,000 were allocated to the Warrants and $ 4,078,025 of the residual proceeds were allocated to the Series A Preferred Stock. $ 330,781 of the additional cash proceeds of $ 1,053,000 were allocated to the Warrants and $ 722,219 of the residual proceeds were allocated to the Series A Preferred Stock from the January 14, 2025 settlement, with all the same terms as the first settlement above. The Mezzanine Equity during the period from April 9, 2025 through September 30, 2025 had converted to 4,939,808 shares of common stock. Of the original 1,775,750 shares of Series A Preferred Stock, a total of 273,750 and 1,383,250 shares were converted during the three months and nine months ended September 30, 2025, respectively. 27 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 8 — REDEEMABLE PREFERRED STOCK, MEZZAININE EQUITY AND WARRANT LIABILITY (cont.) Based on the terms of the Warrants and in accordance with ASC 815, the Warrants are accounted for as a liability due to the variable exercise price subject to adjustment. Currently, there is not an observable market for this type of derivative. Due to the lack of relevant and market reflective Level 1 and Level 2 inputs, the Company valued the Warrant liability using Level 3 inputs, which require significant judgment and estimates on behalf of management in developing model assumptions. The Company determined the value of the Warrant liability using a Binomial Simulation, which takes into consideration the fair market value of the Company’s stock, the variable nature of the exercise price, the estimated exercise period, the volatility of its common stock, and the risk-free interest rate. The following assumptions were made as of December 31, 2024 in the model: (1) a variable exercise price with a floor of $ 4.40 per share, (2) current common stock price of $ 4.28 per share December 31, 2024, (3) discount rate of 4.38 %, and (4) expected stock price volatility of 24.90 %. As of December 31, 2024, the carrying value of the Warrant liability in aggregate was $ 1,971,975 on December 31, 2024. The following assumptions were made as of January 14, 2025 in the model: (1) a variable exercise price with a floor of $ 4.40 per share, (2) current common stock price of $ 4.16 per share on January 14, 2025, (3) discount rate of 4.59 %, and (4) expected stock price volatility of 25.77 %. As of January 14, the carrying value of the 263,250 issued warrants was $ 330,781 . The following assumptions were made as of April 9, 2025 based on stockholder approval in the model for the aggregate warrants: (1) a fixed exercise price of $ 1.12 per share, which automatically reset and resulted in a reclassification of the warrant liability on April 9, 2025 to equity per ASC 815; (2) then-current common stock price of $ 1.34 per share on April 9, 2025; (3) discount rate of 4.06 %; and (4) expected stock price volatility of 23.26 %. As of September 30, 2025, the carrying value of the Warrant liability in aggregate was $0 . For the nine months ended September 30, 2025, the Company recorded a gain on the change in fair value of the Warrant Liability in the amount of $ 1,424,603 and a $ 878,153 deduction due to reclassification to equity. As of September 30, 2025 and December 31, 2024, the carrying value of the Warrant liability in aggregate was $0 and $ 1,971,975 , respectively. The Series A Preferred Stock and Warrants were issued in a basket transaction. When two or more instruments are issued in a basket transaction and some instruments will be remeasured at fair value, the proceeds are first allocated to the instruments recorded at their fair value. Next, the residual method is used to allocate the proceeds to the instrument(s) that are not remeasured at fair value. In this case, the Warrant is subsequently measured at fair value, and the Series A Preferred Stock instrument is measured at initial carrying value. The Company will first allocate the proceeds to the Warrant liability, with the residual allocated to the Series A Preferred Stock liability. The following tables reflect the allocation of the cash proceeds and changes in Warrant Liability in the consolidated statement of operations as of and for the period from December 31, 2024 to September 30, 2025. As of September 30, 2025 Cash proceeds $ 7,103,000 Fair value of Warrant liability ( 2,302,756 ) Residual value allocated to Series A Preferred Stock ( 4,800,244 ) Unallocated cash proceeds $ - For the nine months ended September 30, 2025 Warrant Liability as of December 31, 2024 $ 1,971,975 Additional Warrant Liability on January 14, 2025 330,781 Gain on the change in fair value of Warrant Liability as of March 31, 2025 ( 1,122,561 ) Warrant Liability as of March 31, 2025 1,180,195 Gain on the change in fair value of Warrant Liability as of April 9, 2025 ( 302,042 ) Stockholder approval on April 9, 2025 - warrants turn into Equity ( 878,153 ) Warrant Liability as of September 30, 2025 $ — 28 OS Therapies Incorporated Notes to the Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) NOTE 9 — SEGMENT AND GEOGRAPHIC INFORMATION The Company operates as one operating segment. The Company’s chief operating decision maker (“CODM”) is its Chief Executive Officer , who reviews financial information presented on a consolidated basis. The CODM uses consolidated operating margin and net income to assess financial performance and allocate resources. These financial metrics are used by the CODM to make key operating decisions, such as the determination of the rate at which the Company seeks to grow global operating margin and the allocation of budget between cost of revenues, sales and marketing, technology and development, and general and administrative expenses. The following table presents selected financial information with respect to the Company’s single operating segment for the three and nine months ended September 30, 2025 and 2024: For the three months ended For the three months ended For the nine months ended For the nine months ended September 30, September 30, September 30, September 30, 2025 2024 2025 2024 OPERATING EXPENSES Research & Development $ 3,755,335 $ 1,210,216 $ 7,563,988 $ 1,968,591 General & Administrative 3,124,260 1,227,177 9,153,821 1,878,831 Loss from Operations ( 6,879,595 ) ( 2,437,393 ) ( 16,717,809 ) ( 3,847,422 ) OTHER INCOME/EXPENSE Interest Income 65 - 195 1 Interest Expense - ( 437,839 ) - ( 2,044,283 ) Change in Fair Value of Warrant Liability - - 1,424,603 - TOTAL OTHER INCOME/EXPENSE 65 ( 437,839 ) 1,424,798 ( 2,044,282 ) NET LOSS ( 6,879,530 ) ( 2,875,232 ) ( 15,293,011 ) ( 5,891,704 ) NOTE 10 — SUBSEQUENT EVENTS Series A Warrant Exercises – On October 15, 2025, Series A Warrants were exercised for an aggregate of 1,250,000 prepaid shares of common stock, 950,000 of which were paid for and issued and 300,000 shares of which have been paid for and are available for issuance at a future date. On November 12, 2025, Series A Warrants were exercised for an aggregate of 558,036 prepaid shares of common stock, which have been paid for and are available for issuance at a future date. Ayala Share Issuance – On November 3, 2025, following stockholder approval at the Company’s 2025 annual meeting of stockholders, the Company issued to Ayala 444,041 shares of common stock owed to it pursuant to the HER2 Purchase Agreement. Filing of Registration Statement on Form S-3 – On August 8, 2025, the Company filed a registration statement on Form S-3, containing (i) a base prospectus, which covers the offering, issuance and sale by the Company of up to $ 100,000,000 in the aggregate of the securities identified therein from time to time in one or more offerings, and (ii) an at the market offering prospectus supplement, which covers the offer, issuance and sale of up to a maximum aggregate offering price of up to $ 18,000,000 of the Company’s common stock that may be issued and sold from time to time under an at market issuance sales agreement. As of the date of this report, the Company has sold an aggregate of 189,600 shares of common stock under the market issuance sales agreement. Annual Meeting Approvals – On October 21, 2025, the Company held its 2025 annual meeting of stockholders, whereby the stockholders approved the following proposals, among others: (i) the issuance to Ayala of 441,041 shares owed to it pursuant to the HER2 Purchase Agreement, (ii) an amendment of the Company’s third amended and restated certificate of incorporation, as amended, to increase the number of shares of the Company’s common stock authorized for issuance thereunder from 50 million to 150 million, (iii) an amendment to the Company’s 2023 Incentive Compensation Plan, as amended, to (a) increase the number of shares of common stock available for issuance thereunder from 4 million to 10 million and (b) increase the maximum number of shares of common stock granted to any one individual that is intended to qualify as “performance-based compensation” and (iv) a resolution approving a shareholder rights agreement and authorizing the Company’s board of directors to adopt and implement such shareholder rights agreement at such time, if any, as the Company’s board of directors determines to be appropriate and in the best interests of the Company. 29